RARE vs SLS · rev $350.0M vs $1.62B cap
Ultragenyx (RARE) versus Sellas Life Sciences Group Inc (SLS) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Sellas Life Sciences Group Inc (SLS) is a biotechnology company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported SLS revenue for 2026-06-30 was $0. Net income was -$18.0M. SLS currently screens at market cap $1.62B.
RARE currently screens at market cap $2.79B. SLS currently screens at market cap $1.62B.
Not investment advice. Open the RARE and SLS stock pages for the full models.
Not investment advice.